IGM Biosciences (IGMS) Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IGM Biosciences in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IGMS shares.
View IGMS analyst ratings or view top-rated stocks.

8 brokerages have issued 12-month price targets for IGM Biosciences' shares. Their IGMS share price forecasts range from $17.00 to $55.00. On average, they anticipate the company's stock price to reach $29.78 in the next twelve months. This suggests a possible upside of 161.9% from the stock's current price.
View analysts price targets for IGMS or view top-rated stocks among Wall Street analysts.

IGM Biosciences' stock was trading at $17.01 at the beginning of the year. Since then, IGMS shares have decreased by 33.2% and is now trading at $11.37.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our IGMS earnings forecast.

IGM Biosciences, Inc. (NASDAQ:IGMS) posted its earnings results on Thursday, March, 30th. The company reported ($1.19) earnings per share for the quarter, beating the consensus estimate of ($1.53) by $0.34. The business earned $0.37 million during the quarter, compared to the consensus estimate of $15.27 million. IGM Biosciences had a negative trailing twelve-month return on equity of 74.30% and a negative net margin of 14,363.10%. During the same period last year, the firm earned ($1.50) earnings per share.

ETFs with the largest weight of IGM Biosciences (NASDAQ:IGMS) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC), iShares Biotechnology ETF (IBB), ProShares Ultra Nasdaq Biotechnology (BIB) and

Based on aggregate information from My MarketBeat watchlists, some companies that other IGM Biosciences investors own include Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), ImmunoGen (IMGN), Plug Power (PLUG), Atreca (BCEL), Carnival Co. & (CCL), Cisco Systems (CSCO), Dropbox (DBX) and Energy Transfer (ET).

(IGMS) raised $125 million in an initial public offering (IPO) on Wednesday, September 18th 2019. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

IGM Biosciences trades on the NASDAQ under the ticker symbol "IGMS."

IGM Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (4.92%), FMR LLC (1.96%), BlackRock Inc. (1.79%), State Street Corp (0.53%), Geode Capital Management LLC (0.46%) and Candriam S.C.A. (0.44%). Insiders that own company stock include Bruce Keyt, Chris H Takimoto, Daniel Shinyu Chen, Fred Schwarzer, George Gauthier, Jakob Haldor Topsoe, Julie Hambleton, M Kathleen Behrens, Michael D Loberg, Misbah Tahir and Redmile Group, Llc.
View institutional ownership trends.

Shares of IGMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IGMS stock can currently be purchased for approximately $11.37.

IGM Biosciences (NASDAQ:IGMS) has a market capitalization of $489.82 million and generates $1.07 million in revenue each year. The company earns $-221,100,000.00 in net income (profit) each year or ($5.17) on an earnings per share basis.

The company employs 192 workers across the globe.

IGM Biosciences' mailing address is 325 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The official website for the company is igmbio.com. The company can be reached via phone at 650-965-7873.